Table 2.
Cancer type | Accession number | Number of samples (tumor/normal) | P-value | References |
---|---|---|---|---|
Upregulated | ||||
Hepatocellular carcinoma | GSE14520 | 233/233 | < 0.0001 | [57, 58] |
Breast carcinoma | GSE10780 | 42/143 | 0.0002 | [59] |
Gastric cancer | GSE13861 | 71/19 | 0.0388 | [60] |
Ovarian cancer | GSE14407 | 12/12 | 0.0438 | [61] |
Downregulated | ||||
Pancreatic cancer | GSE28735 | 45/45 | 0.0003 | [62, 63] |
Colorectal cancer | GSE32323 | 17/17 | 0.0011 | [64] |
Insignificant | ||||
Melanoma | GSE3189 | 45/7 | 0.0848 | [65] |
Bladder cancer | GSE3167 | 41/9 | 0.1243 | [66] |
Acute lymphoblastic leukemia | GSE26713 | 117/7 | 0.2168 | [67] |
Renal clear cell carcinoma | GSE36895 | 23/23 | 0.2445 | [68] |
Esophageal carcinoma | GSE23400 | 53/53 | 0.2526 | [69, 70] |
Nasopharyngeal carcinoma | GSE12452 | 31/10 | 0.2710 | [71–73] |
Lung cancer | GSE30219 | 293/14 | 0.2938 | [74] |
Prostate cancer | GSE6919 | 58/58 | 0.7478 | [75, 76] |
P-values were acquired through t-test for the comparison of PEG10 expression between cancer and normal